Novartis

Charting patient pathways with precision for better healthcare

Patients and physicians are stronger together and Dunlop, who has more than 20 years’ experience leading patient advocacy programmes and engagement strategies for clients such as AstraZeneca, GSK, Novartis and Pfizer,

Novartis and Voyager Therapeutics agree on gene therapy deal worth 1.7bn

Novartis has announced a licence option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids to use in potential gene ... Voyager will receive an initial $54m

Sandoz launches generic oncology treatment in Europe

Sandoz, a division of Novartis, is a global company working to address unmet medical needs and provide patients with access to generic pharmaceuticals and biosimilars.

Novartis to pay up to $1.5bn for Gyroscope

There are no approved treatments, making it ‘one of the most significant unmet needs remaining in retinal diseases’, according to Novartis. ... in ocular gene therapies that will position us well to continue developing this promising one-time

Novartis strengthens links with BeiGene in a deal that could be worth up to $1bn

The two companies are already working together after Novartis signed an in-licensing agreement for BeiGene’s anti-PD-1 monoclonal antibody, tislelizumab. ... countries. Basel-based Novartis will also pay a fee of up to $700m if the option is exercised

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]